NASDAQ:MDXG MiMedx Group (MDXG) Stock Price, News & Analysis $6.15 -0.23 (-3.61%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$6.13▼$6.4850-Day Range$6.15▼$7.7652-Week Range$5.57▼$9.27Volume461,505 shsAverage Volume757,823 shsMarket Capitalization$907.76 millionP/E Ratio13.98Dividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MiMedx Group alerts: Email Address MiMedx Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside95.1% Upside$12.00 Price TargetShort InterestHealthy3.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth15.38%From $0.26 to $0.30 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.57 out of 5 starsMedical Sector235th out of 910 stocksSurgical & Medical Instruments Industry29th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingMiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMiMedx Group has only been the subject of 2 research reports in the past 90 days.Read more about MiMedx Group's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.27% of the outstanding shares of MiMedx Group have been sold short.Short Interest Ratio / Days to CoverMiMedx Group has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in MiMedx Group has recently decreased by 0.62%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMiMedx Group does not currently pay a dividend.Dividend GrowthMiMedx Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDXG. Previous Next 1.9 News and Social Media Coverage News SentimentMiMedx Group has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for MiMedx Group this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for MDXG on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added MiMedx Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MiMedx Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of MiMedx Group is held by insiders.Percentage Held by Institutions79.15% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MiMedx Group's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for MiMedx Group are expected to grow by 15.38% in the coming year, from $0.26 to $0.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiMedx Group is 13.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.71.Price to Earnings Ratio vs. SectorThe P/E ratio of MiMedx Group is 13.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.06.Price to Book Value per Share RatioMiMedx Group has a P/B Ratio of 5.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MiMedx Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About MiMedx Group Stock (NASDAQ:MDXG)MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.Read More MDXG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDXG Stock News HeadlinesSeptember 6 at 4:41 AM | americanbankingnews.comMiMedx Group (NASDAQ:MDXG) Rating Increased to Strong-Buy at StockNews.comSeptember 5 at 11:54 AM | markets.businessinsider.comMiMedx Group (MDXG) Gets a Buy from Northland SecuritiesSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.September 4 at 4:23 PM | prnewswire.comTHIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'September 1, 2024 | americanbankingnews.comMiMedx Group (NASDAQ:MDXG) Sees Large Volume IncreaseAugust 29, 2024 | finance.yahoo.comMiMedx Group (NASDAQ:MDXG) shareholders have endured a 56% loss from investing in the stock three years agoAugust 29, 2024 | americanbankingnews.comMiMedx Group, Inc. (NASDAQ:MDXG) Receives Consensus Rating of "Buy" from BrokeragesAugust 26, 2024 | prnewswire.comDEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUITSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 21, 2024 | seekingalpha.comBioStem Technologies: A New Growth Star In Health CareAugust 1, 2024 | msn.comMiMedx Group Non-GAAP EPS of $0.08 in-line, revenue of $87.21M misses by $1.71MJuly 31, 2024 | globenewswire.comMIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen MatrixJuly 31, 2024 | globenewswire.comMIMEDX Announces Second Quarter 2024 Operating and Financial ResultsJuly 29, 2024 | finance.yahoo.comMDXG: Final Note Before Wednesday’s EarningsJuly 26, 2024 | markets.businessinsider.comCraig-Hallum Gives a Buy Rating to MiMedx Group (MDXG)July 22, 2024 | globenewswire.comMIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific ReportsJuly 19, 2024 | finance.yahoo.comMIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31July 1, 2024 | investorplace.com7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsSee More Headlines Receive MDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:MDXG CUSIPN/A CIK1376339 Webwww.mimedx.com Phone(770) 651-9100Fax678-384-6741Employees870Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$14.00 Low Stock Price Target$11.00 Potential Upside/Downside+95.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.44 Trailing P/E Ratio13.98 Forward P/E Ratio23.65 P/E GrowthN/ANet Income$58.23 million Net Margins23.63% Pretax Margin17.03% Return on Equity34.24% Return on Assets18.20% Debt Debt-to-Equity Ratio0.11 Current Ratio3.85 Quick Ratio3.22 Sales & Book Value Annual Sales$340.46 million Price / Sales2.67 Cash Flow$0.17 per share Price / Cash Flow36.38 Book Value$1.14 per share Price / Book5.39Miscellaneous Outstanding Shares147,604,000Free Float145,685,000Market Cap$907.76 million OptionableOptionable Beta1.98 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Joseph H. Capper (Age 60)CEO & Director Comp: $1.55MMr. Douglas C. Rice CPA (Age 58)Chief Financial Officer Comp: $470.47kMr. William F. Hulse IV (Age 50)General Counsel & Chief Administrative Officer Comp: $959.59kMr. Scott M. Turner (Age 58)Senior Vice President of Operations & Procurement Comp: $493.98kMr. Matthew M. NotarianniHead of Investor RelationsMr. Mark P. Graves (Age 58)Senior VP & Chief Compliance Officer Hilary DixonVice President of Investor Relations & Corporate Strategic CommunicationsMs. Kate SurdezChief Human Resources OfficerDr. David H. Mason Jr. (Age 77)Chief Medical Officer Dr. Robert Benjamin Stein M.D. (Age 73)Ph.D., President of Regenerative Medicine & Biologics Innovation Comp: $639.28kMore ExecutivesKey CompetitorsAlphatecNASDAQ:ATECIntersect ENTNASDAQ:XENTCryoLifeNYSE:CRYOrthofix MedicalNASDAQ:OFIXAnika TherapeuticsNASDAQ:ANIKView All CompetitorsInsiders & InstitutionsTruist Financial CorpBought 35,000 shares on 8/21/2024Ownership: 0.036%Point72 Asset Management L.P.Bought 5,800 shares on 8/19/2024Ownership: 0.004%Nemes Rush Group LLCBought 7,844 shares on 8/16/2024Ownership: 0.011%Algert Global LLCSold 46,916 shares on 8/16/2024Ownership: 0.008%The Manufacturers Life Insurance Company Bought 3,222 shares on 8/15/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions MDXG Stock Analysis - Frequently Asked Questions How have MDXG shares performed this year? MiMedx Group's stock was trading at $8.77 at the start of the year. Since then, MDXG shares have decreased by 29.9% and is now trading at $6.15. View the best growth stocks for 2024 here. How were MiMedx Group's earnings last quarter? MiMedx Group, Inc. (NASDAQ:MDXG) posted its quarterly earnings data on Wednesday, July, 31st. The company reported $0.08 EPS for the quarter, meeting analysts' consensus estimates of $0.08. The firm earned $87.21 million during the quarter, compared to analysts' expectations of $88.44 million. MiMedx Group had a trailing twelve-month return on equity of 34.24% and a net margin of 23.63%. Who are MiMedx Group's major shareholders? Top institutional shareholders of MiMedx Group include Paradigm Capital Management Inc. NY (2.82%), Renaissance Technologies LLC (1.06%), Dimensional Fund Advisors LP (0.88%) and Richmond Brothers Inc. (0.62%). Insiders that own company stock include Timothy R Wright, William Frank Iv Hulse, Rohit Kashyap, Robert Benjamin Stein, Scott M Turner, William Lawrence Phelan and Mark Graves. View institutional ownership trends. How do I buy shares of MiMedx Group? Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MDXG) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiMedx Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiMedx Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.